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Abstract
Objective: To assess the effect of immuno-chemotherapy on the extent of local tumour recurrence in an established rat model of malignant
pleural mesothelioma (MPM). Methods: Six days after subpleural inoculation of a syngeneic MPM cell line Interleukin-45 (IL-45), left-sided
pneumonectomy and resection of the tumour nodule was performed. Animals were randomised into four treatment groups for intrapleural
therapy: control (n = 6), 500 mg cytosine phosphate guanosine oligodeoxynucleotide (CpG-ODN) (n = 6), cisplatin-fibrin (n = 6), cisplatin-
fibrin + 500 mg CpG (n = 6). Six days later the volume of tumour recurrence was assessed, which was the primary endpoint. Secondary endpoints
were quantification of the ratio host/tumour cells in the local recurrence and cytokine expression profile in the tumour tissue by real time
quantitative PCR (qPCR). T lymphocyte subpopulations in the tumour recurrence tissue were evaluated by immunohistochemistry. Treatment-
related toxicity was monitored by measuring blood chemistry and complete blood count. Results: The volume of tumour recurrence was
significantly reduced from 610 mm3 in the control group to 11.7 mm3 in the cisplatin-fibrin group (p = 0.004) and to 21.8 mm3 in the cisplatin-
fibrin + CpG group ( p = 0.004). Pro-inflammatory cytokines (Interferon-g (IFN-g), Interleukin-6 (IL-6), Interleukin-12 (IL-12)) were increased after
treatment with cisplatin-fibrin + CpG in comparison to cisplatin-fibrin alone but differences were not statistically significant. We found a higher
ratio of host/tumour cells in the cisplatin-fibrin + CpG group (45/55%) compared to the cisplatin-fibrin group (27/73%). In comparison to the
control group, animals treated with cisplatin-fibrin + CpG showed a higher number of CD8+ T-cells in the tumour tissue. No significant treatment-
related toxicity was observed. Conclusions: Adjuvant treatment with chemotherapy or immuno-chemotherapy leads to significant reduction of
mesothelioma recurrence after surgery in this rat MPMmodel. Immuno-chemotherapy resulted in an increased recruitment of inflammatory cells
to the site of tumourigenesis and elicited higher level of tumour growth inhibiting cytokines.
# 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Asbestos is a known carcinogen. Its use has been banned
from the European Union since 2005 [1]. Due to the time lag
between asbestos exposure and cancer development, initial
analysis predicted that malignant pleural mesothelioma
(MPM) related deaths will continue to increase and peak in
the year 2020 [1]. Recent analysis suggests that the increase
may be levelling off and the peakmight be anticipated earlier
than predicted, around 2015 [2].§ Presented at the 16th European Conference on General Thoracic Surgery,
Bologna, Italy, June 8—11, 2008.
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doi:10.1016/j.ejcts.2008.11.030In some villages in Turkey asbestosis is present in the
environment, this results in a rate of mesothelioma-related
mortality more than 100 fold higher than in control villages.
The clinical course of mesothelioma disease is characterised
by locally aggressive growth of the tumour. Multimodality
treatment including chemotherapy, surgery and radiotherapy
can offer a long-term survival [3,4].
However, despite this aggressive approach, local recur-
rence still remains the main problem of this type of tumour
[4]. Hence, new therapeutic strategies are required.
Intrapleural chemotherapy provides the advantage to
achieve high local concentration while reducing systemic
side effects and has been used in clinical and experimental
settings [5—9].
Using our previously established ratmesotheliomamodel of
tumour recurrence, we demonstrated a significant reduction
of tumour recurrence by intrapleural chemotherapy withSurgery. Published by Elsevier B.V. All rights reserved.
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groups have shown that intrapleural application of different
immunomodulating therapies such as cytokines affected local
tumour growth in MPM patients. Interleukin-2 (IL-2), for
example, enhances the cytotoxic response of activated T-cells
[8] and it has been proven to be superior to Interferon-a (IFN-
a) and Interferon-b (IFN-b) in neoplastic pleural effusion and
solid tumour comprised mesothelioma [8]. Lucchi et al.
reported on the combination of IL-2 and chemotherapy in the
multimodality treatment of malignant pleural mesothelioma
patients [9].
One particularly promising approach is the stimulation of
the innate immunity [6,7]. Toll-like receptors (TLRs) are
pattern recognition receptors. They recognise conserved
motifs of micro-organisms; their stimulation results in
activation of the innate immune response, including release
of cytokines, up-regulation of activation markers and of MHC
molecules [6,7]. Currently, 13 TLRs (11 with known ligands)
are described. TLRs differ by their cellular expression
pattern, their recognition of conserved motifs and their
ensuing activation they initiate. We focused our efforts on
triggering TLR9: TLR9 binds preferentially unmethylated DNA
motifs containing cytosine and guanosine, mainly present in
bacteria and viruses. Synthetic TLR9 ligands containing
unmethylated cytosine phosphate guanosine oligodeoxynu-
cleotide (CpG-ODN) were generated and their value studied
mainly for targeted immunomodulation. In fact, unmethy-
lated CpG motifs are known to direct a strong immunosti-
mulation of human B-lymphocytes, monocytes/
macrophages, and dendritic cells. In addition, CpG induces
the release of Th1-type cytokines such as Interleukin-12 (IL-
12), Interleukin-6 (IL-6) and TNF-a, resulting in the activation
of natural killer (NK) cells [8]. Chemotherapy and immu-
notherapy with CpG have synergistic effects [9] in several
human and animal tumourmodels [10—14]. In amurinemodel
of peritoneal mesothelioma, CpG resulted in a decrease of
tumour growth and mortality when given intraperitoneally in
combination with coramsine [10]. Currently there are no
reports about CpG-based immunotherapy for malignant
pleural mesothelioma.
In our rat mesothelioma recurrence model, we studied if
CpG reduces the volume of tumour recurrence after surgical
resection when applied intrapleurally either alone or in
combination with chemotherapy. Furthermore we assessed
the inflammatory response to this immunomodulating treat-
ment at the tumour site.2. Materials and methods
2.1. In vitro study
Prior to the in vivo study, we performed in vitro
experiments in order to assess whether rat cells are
susceptible to CpG treatment: peripheral blood mononuclear
cells (PBMC) and the cells of our syngeneic rat mesothelioma
cell line (II-45) [15] were treated with different dosages of
either 500 ng/ml or 5000 ng/ml of CpG and thereafter
Interferon-g (IFN-g), IL-6 and TNF-a were analysed in the
supernatant by multiplex technology as described by
Lagrelius et al. [16] by Cytolab (www.cytolab.ch).2.2. In vivo study
The study protocol was approved by the local veterinary
committee. Male Fisher rats weighing 260—300 g (Harlan,
The Netherlands) were used. The animals were housed in the
animal facility of the University Hospital of Zurich; after
arrival, rats were acclimatised for 10 days prior to any
experiments. They received humane care in accordance with
the ‘Guide for the Care and Use of Laboratory Animals’
(National Institutes of Health publication no. 86-23, revised
1985).
2.3. Dose-escalating study to define the optimal dose of
CpG
We initially performed a dose-escalating study in order to
define the optimal dose based on the cytokine expression in
the pleural tissue and considering treatment-related toxicity.
The CpG28 (Microsynth AG, Balgach, Switzerland) has been
previously evaluated to stimulate the rat-specific TLR9 [7];
its sequence is 50-TAAACGTTATAACGTTATGACGTCAT-30; phos-
phorothioate bonds were present at any position for
stabilisation of the oligodeoxynucleotide. CpG were HPLC-
purified followed by dialysis. Before using, CpG were
resuspended in NaCl.
Under general anaesthesia, a suspension of 50 ml contain-
ing three increasing different dosages of CpG was inoculated
with a syringe (25 Gauge, 0.5  16 mm) under the parietal
pleura via a small left-sided thoracotomy in the fifth
intercostal space according to the following experimental
design: group 1 (n = 3): control, untreated animals; group 2
(n = 3): 100 mg CpG; group 3 (n = 3): 500 mg CpG; group 4
(n = 3): 1000 mg CpG.
The rats were weighed before each surgical procedure and
before any blood draw. Blood draws were obtained every
other day to assess treatment-related toxicity by measuring
the level of haemoglobin, haematocrit, leucocytes, plate-
lets, urea, creatinine and transaminases. Six days after the
instillation of CpG into the pleural space, the rats were
euthanised and the chest wall was removed for evaluation of
the cytokine expression profile, i.e., IL-12, IL-6 and IFN-g, in
the pleural tissue. Notably, pleural samples from the CpG site
of injection into tumour tissue and approximately 2 cm away
from the injection sites were taken. The samples were snap-
frozen in liquid nitrogen and stored at 80 8C. Similarly,
serum was analysed for its cytokine profile.
2.4. PCR assays
For quantitative PCR (qPCR), rat-specific primers for
Interleukin-6, Interleukin-12, Interferon-g, Interferon-a and
Interferon-b were purchased from Qiagen AG (Hombrechti-
kon, Switzerland). Tumour specimens were processed for
total RNA extraction using Qiagen RNAeasyW. From the
extracted RNA, reverse transcription was performed on 400—
500 ng RNA (Qiagen QuantiTectW Reverse Transcription
protocol). To investigate the quantitative expression of IL-
6, IL-12 and IFN-g, cDNA were amplified by the SYBR-Green
PCR assay using Quantitect primer (Qiagen), and products
were detected on a Prism 5700 detection system (SDS, ABI/
Perkin-Elmer). We verified the specificity of the qPCR by
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keeping gene. Cytokine levels were expressed relative to the
housekeeping genes by comparing (a) PCR cycle threshold
between cDNA of cytokines and GAPDH (DC), and (b) DC
values between different DC values and the highest DC
(DDC).
2.5. Treatment strategy
We used a syngeneic mesothelioma tumour recurrence
model as previously described [5]. Briefly, one million cells of
a syngeneic mesothelioma cell line were injected into the
subpleural space. Six days later, the tumour nodule which was
grown meanwhile at the injection site was macroscopically
completely resected and a left-sided pneumonectomy plus
pleural abrasion was performed; this procedure was intended
to imitate the treatment strategy of extrapleural pneumo-
nectomy in humans. After resection, we applied the
intrapleural treatment according to the following experi-
mental design: (1) control, untreated animals (no adjuvant
treatment); (2) cisplatin (100 mg/m2) loaded to fibrin; (3)
50 ml of a CpG solution with a concentration of 10 mg/ml at
the site of the tumour resection; and (4) combined treatment
of cisplatin loaded to fibrin and CpG (see above); the number
in each group was six. The randomisation process was
performed prior to the start of the experiment before
inoculation of the tumour cells. For the treatment in groups 2
and 4, cisplatin was loaded to a fibrin-based carrier called
VivostatW as described previously [17]. CpG was injected
subpleurally at the site of tumour nodule resection. Six days
after treatment, the rats were euthanised and the chest wall
dissected for analysis. Blood draws were taken daily to assess
the possible treatment-related toxicity (see above). The
primary endpoint was the volume of tumour recurrence. The
length, width and thickness of the tumour nodule were
accurately measured and the volume of the recurrence
evaluated using the formula: V = 4/3p abc (a, b, c = semi-
axes of the tumour).
In order to determine the amount of tumour cells
recurring we took advantage of the fact that the tumour
cell line, II-45 cells are originally derived from a female rat
[15] and are implanted in male rats. By comparing the levels
of Y chromosome-gene sex determining region Y (SRY) versus
the non-sex specific gene Rev3 allows determining the
amount of host tissue in the whole specimen. Therefore,
tumour samples were processed for DNA extraction using
DNAeasy (Qiagen) and quantitative PCR was performed as
described in the PCR section. Relative DNA levels were
determined by comparing (a) PCR cycle threshold between
SRY gene (Qiagen QuantiTect Cat. No. QT00459753) and Rev3
(DC), and (b) DC values between different DC values and the
highest DC (DDC).
Secondary endpoints were the cytokine expression profile
in the serum and in the tumour tissue as well as treatment-
related toxicity (see above). Cytokine expression in the
tumour tissue was evaluated by qPCR as described before.
Cytokine levels were measured in the serum by Cytolab
(www.cytolab.ch) using multiplex technology. The white
blood cell subpopulations including T-cells, NK-cells, and
macrophages were assessed by immunohistochemistry in
biopsy specimens of tumour recurrence. For this purpose, weconstructed a tissue micro-array with biopsies of the tumour
tissue at the time point of primary tumour resection and
autopsy: sections (4.5 mm) of tissue were transferred to an
adhesive-coated slide system (Instrumedics, Hackensack, NJ,
USA). Sections were manually stained after heat-induced
epitope retrieval (3 min, 110 8C, citrate buffer, pH 6.0) using
a standard multilink detection kit (Medi-Stain HRP DAB,
mediteAG, Nunnigen, CH, Switzerland). The primary anti-
bodies were purchased by Serotec AbD (MorphoSys AbD
GmbH, Duesseldorf, Germany): monoclonal anti-rat CD3
(1F4; MCA772), anti-rat CD8 (OX-8; MCA48GA), anti-rat
CD161 (10/78; MCA1427GA) and anti-rat CD68 (ED1;
MCA341GA) diluted according to the manufacturer’s proto-
col. The sections were assessed by two observers (A.S., L.A.).
The number of positive stained cells were counted and a
semi-quantitatively score was adopted as follows: 0 for 0—2
cells/core; 1 for 3—10 cells/core; 2 for 11—50 cells/core; and
3 for >50 cells/core.
The software package SPSS for Windows, version 15.0
(SPSS Inc., Chicago, Illinois) was used for the statistical
analysis. Kruskal—Wallis test was performed to compare all
groups; p values below 0.05 were considered significant.
Mann—Whitney test was used for comparisons between single
groups. Bonferroni correction was applied for multiple
comparisons. A p value below 0.008 was then considered
significant.3. Results
3.1. In vitro study
The qPCR confirmed that TLR9was expressed in peripheral
blood mononuclear cells of Fisher rats and showed that
cytokine expression increased in PBMC in response to CpG28:
in particular, the higher the dosage of CpG injected, the
higher expression level of cytokines found (data not shown).
3.2. Dose-escalating study to define the optimal dose of
CpG
All animals were fine irrespective of the dose applied. In
particular there was neither a significant difference in the
weight nor differences in the haematological, renal or
hepatic parameters measured in the blood during the
observation period. qPCR for detection of different cytokines
in the pleural samples taken at the site of CpG injection and
far from the site of injection, revealed increased levels of
pro-inflammatory cytokines (IL-6, IL-12 and IFN-g) of the
treated groups in comparison to the control group (Table 1).
Similar changes of IFN-a and IFN-b expression were not
detected. We did not see any increase of local cytokine
expression in the pleural tissue when the dosage of CpG
instilled was increased from 500 to 1000 mg. In the serum,
TNF-a peaked the first day after treatment start, which was
more pronounced after application of the higher dosages of
CpG (Table 2); however, that was not the case for IFN-g and
IL-6 expression in the serum. Based on these results, a dosage
of 500 mg CpG was chosen for further investigation in our rat
recurrence model.
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Fig. 1. Successful treatment of mesothelioma tumour with cisplatin-fibrin and
cisplatin-fibrin + CpG. Photographs show ipsilateral chest wall at the time
point of autopsy six days after intrapleural treatment; (A) control group:
arrow indicating tumour recurrence, (B) CpG 500 mg group: arrow indicating
tumour recurrence, (C) cisplatin-fibrin group: tumour recurrence macrosco-
pically not visible, and (D) cisplatin-fibrin + CpG 500 mg group: tumour recur-
rence macroscopically not visible.
Fig. 2. Minimal tumour recurrence with cisplatin-fibrin or cisplatin-
fibrin + CpG. In each group of rats n = 6. Results presented as box-plot of
volume of tumour recurrence. Initially a Kruskal—Wallis test was performed
( p = 0.001) and subsequently a Mann—Whitney test was performed for multiple
comparison between the different groups: comparison between cisplatin-
fibrin to control ( p = 0.004) and cisplatin-fibrin + CpG to control
( p = 0.004). Control group: mean volume 610 mm3 (284); CpG group: median
volume 442 mm3 (1002); Cisplatin-fibrin group: median volume 12 mm3
(15); Cisplatin-fibrin + CpG group: median volume 22 mm3 (2).
Table 1
Dose-escalating pilot study: IFN-g and IL-6 expression levels in the pleural
tissue in the different groups. Data are given in mean and SD.
IFN-g expression levels
Pleural tissue
Groups Site of injection Far from site of injection
Control 99.45  99.1 99.45  99.2
CpG 100 mg 244.12  422.8 295.62  59.1
CpG 500 mg 397.74  274.6 259.22  82.3
CpG 1000 mg 258.26  172.7 199.98  79.1
IL-6
Control 997.23  1068.1 997.23  1068.1
CpG 100 mg 14680.17  22692.1 2930.88  3363.2
CpG 500 mg 9798.3  10409.1 1861.93  2056.4
CpG 1000 mg 12433.41  5744.6 1790.94  2391.3
Table 2
Dose-escalating pilot study: TNF-a levels in the serum. Data are given in mean
and SD.
TNF-a
Serum (pg/ml)
Groups Baseline 1 day 2 days 6 days (autopsy)
Control 3  0.2 3  1.1 3  0.7 6.5  1.9
CpG 100 mg 4.9  2.4 4.9  1.9 3  2.1 3  1.3
CpG 500 mg 4.8  2.1 7.25  1.9 3  1.8 3  3.1
CpG 1000 mg 3  2.8 14.4  4.2 3  0.9 3.35  2.63.3. Treatment strategy
All animals survived until the end of the observation
period of six days. Six days after inoculation, all animals had a
tumour nodule of a mean diameter of 5.5  0.7 mm at the
injection site. The rats were sacrificed and tumour
recurrence was evaluated six days after the experimental
treatment, which consisted of pneumonectomy, pleural
abrasion and application of the therapy solution according
to the experimental design. All rats presented recurrence at
the resection site whereas they showed no signs of tumour
recurrence or metastases in the contralateral chest cavity or
abdomen. The volume of tumour recurrence was significantly
reduced in the treatment groups (Kruskal—Wallis test
p = 0.001) (Fig. 1). Further analysis showed that cisplatin-
fibrin and cisplatin-fibrin + CpG had significantly reduced
tumour volume with 12 mm3 (15) ( p = 0.004) and 22 mm3
(22) ( p = 0.004), respectively, in comparison to the control
group with 610 mm3 (Fig. 2) but also in comparison to
immunotherapy alone with 442 mm3 ( p = 0.004 and
p = 0.004, respectively).
The histopathological analysis revealed only small tumour
islets remaining in the group of animals treated with
chemotherapy and/or immunotherapy. The difference
between cisplatin-fibrin and cisplatin-fibrin + CpG treated
rats was statistically not significant.
SRY gene determination for differentiation between host
and tumour cells showed higher percentage of host cells
(45%) in the group of animals which received the combination
treatment cisplatin-fibrin + CpG than in the group treated
with cisplatin-fibrin alone (27% of host cells, p = 0.06)
(Fig. 3).The animals treated with combination treatment cispla-
tin-fibrin + CpG showed a higher number of CD8+ T-cells than
animals treated with cisplatin-fibrin alone ( p = 0.07). Two
representative figures of the infiltration with CD8+ T-cells
into the recurrent tumour are shown (Fig. 4). While the
number of NK-cells ( p = 0.08) and macrophages ( p = 0.07)
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Fig. 3. Treatment with cisplatin-fibrin + CpG results in a higher content of host
cells in the tumoural mass in comparison to the other groups. The content of
host versus tumoural cells was determined by means of qPCR analysis of SRY
gene.
Fig. 4. Immuno-chemotherapy results in a prominent infiltration of the resi-
dual tumour mass with CD8+ T-cells. Immunohistochemistry of tumour tissue
obtained from rats treated with cisplatin-fibrin (a) and cisplatin-fibrin + CpG
(b). Representative photographs shown.
Fig. 6. The combination cisplatin-fibrin + CpG resulted in strong stimulation of
IL-12 expression in the tumour tissue as quantified by qPCR which was not the
case in the other treatment groups but differences were not statistically
different (Kruskal—Wallis test p = 0.06).was not significantly higher in the treatment groups, there
was a trend of increased number in the tumour tissue. NK-
cells were in any case very rare, while macrophages were
very much present independently on the treatment.
We found that rats treatedwith cisplatin-fibrin, had a lower
level of IFN-g, IL-6 and IL-12 in the pleural space as compared
to the control group. Notably, while statistically not
significant, the rats treated with cisplatin-fibrin + CpG had a
higher level of IFN-g, IL-6 and IL-12 in the pleural space as
compared to rats treated with cisplatin-fibrin alone (Figs. 5
and 6). In the serum, we found high levels of IL-6, IFN-g and
TNF-a in the cisplatin-fibrin + CpG group as compared to
untreated animals. Blood count, renal and hepatic parametersFig. 5. The combination cisplatin-fibrin + CpG resulted in more important
stimulation of IL-6 expression in the tumour tissue as quantified by qPCR
compared to cisplatin-fibrin alone but differences were not statistically
different (Kruskal—Wallis test: p = 0.07).in the blood samples taken at different time points were
similar between treatment and control group as related to
renal and hepatic chemistry and complete blood count.
Thrombocytes were significantly increased at day 3 in the
group of rats treated with CpG 500 mg alone (data not shown).4. Discussion
In this work we studied the effects of triggering TLR9 on
tumour recurrence in amesothelioma ratmodel. We found no
beneficial effect when TLR ligands were applied alone or no
additional benefit when TLR ligands were added in concert
with chemotherapy. In any case, we observed a significant
reduction of tumour volume after resection and intrapleural
treatment with chemotherapy or combined immuno-che-
motherapy.
The lack of any additional benefit with immuno-che-
motherapy may be explained by the very aggressive sarco-
matoid tumour cells, which result in development of a huge
tumour recurrence in only six days after surgery and the strong
anti-tumour effect of cisplatin-fibrin alone. Indeed, cisplatin
results in a near entire disappearance of the tumour. In
addition, the short observation period of six days after
treatment may not allow for the detection of immuno-
mediated effects. These results were obtained after a single
local injection of 500 mg of CpG after resection and different
results might be obtained if repeated or systemic application
were used. Indeed, in several human and experimental
studies, chemotherapy and immunotherapy with CpG have
shown synergistic effects [10,12—14]: van der Most et al. [10]
reported an enhanced anti-tumour efficacy when combining
intraperitoneal chemotherapy with coramsine together with
CpG-containing oligodeoxynucleotides in a murine model of
malignant peritoneal mesothelioma. Similarly, Carpentier and
co-workers [12—14] reported very impressive tumour reduc-
tion and long-term survival without secondary side effects
when repeated injections of CpG were given intra-tumourally
and thereafter subcutaneously in murine glioma model. Thus,
we speculate that repeated local or systemic injections,
intraperitoneally or subcutaneously, of immunomodulatory
CpG oligodeoxynucleotides may potentiate their anti-tumour
response; a single dose of CpG may be insufficient.
Although the volume of tumour recurrence in rats treated
with immuno-chemotherapy was similar to the rats treated
with chemotherapy, the immuno-chemotherapy resulted in a
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the site of tumour. In fact, almost half of the cells in the
tumour bed were found to be inflammatory cells and not
neoplastic cells. The local increase of pro-inflammatory
cytokines after immunotherapy observed, when given alone
or in combination with chemotherapy reflects an activated
immune system. The mesothelioma cell line was derived
from female rats. Since we exclusively used male rats, we
were able to distinguish within the tumour recurrence
between tumour cells and chemotactically attracted host
cells by using primers specific for the ‘sex determining region
Y gene’ and a reference gene. We found that the percentage
of host cells in animals treatedwith cisplatin-fibrin + CpGwas
45% in comparison to the control rats and rats treated with
cisplatin-fibrin alone with 27%. Immunohistochemical analy-
sis revealed an increased influx of CD8+T-cells into the
tumour recurrence of rats treated with immuno-chemother-
apy compared to rats treated with chemotherapy alone.
Similarly, the immuno-chemotherapy resulted in a pro-
nounced increase of inflammatory cytokine such as IL-6,
IL-12 and IFN-g in the vicinity of the tumour, which was not
the case in the other therapy groups.
Notably, persistent TLR stimulation may break tolerance
against tumour associated antigens; synthetic compounds
may be an ideal adjuvant to the existing chemotherapeutic
approaches. While we have not found an effect of CpG alone
on tumour recurrence, the potent inflammatory reactionmay
be beneficial for anti-tumour killing and perhaps for
generating an adaptive immune response against tumour
antigens, which may limit or slow down tumour growth or
metastasis over a longer time period.
In summary, TLR9 ligands are very promising as an adjunct
to chemotherapy for treating neoplasia. However, we need a
better and more detailed knowledge about the molecular
mechanism(s) of these immunomodulatory compounds and
how we have to apply them. In this study we contributed to
this ever growing field by gathering information on the
inflammatory profile present in chemotherapy versus
immuno-chemotherapy: briefly, we found that local sub-
pleural injection of CpG in combination with chemotherapy
induces a local inflammatory reaction which is not present
with chemotherapy alone.Acknowledgements
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